Wednesday, July 8, 2026

Patent intelligence · US

US 8349894

Compositions comprising an o/w emulsion containing conjugated linoleic acid

granted A61KA61K31/201A61K31/231A61K47/12
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 6
Applicant portfolio 175
Patent details — US 8349894
Jurisdiction
US
Status
granted
Grant date
Jan 8, 2013
Expiration
Jan 3, 2033
Applicant
Aker Biomarine AS
Claims
12
CPC classes
A61K, A61K31/201, A61K31/231, A61K47/12
View on Google Patents ↗

Quick answer

US 8349894 (Compositions comprising an o/w emulsion containing conjugated linoleic acid) is held by Aker Biomarine AS. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Aker Biomarine AS
Grant date
Expiration
Claims
12
CPC classes
A61K, A61K31/201, A61K31/231, A61K47/12, A61K47/14, A61K9/0019

More from Aker Biomarine AS

Related pharmaceutical patents in our USPTO index.

  1. US 12427171

    Krill oil composition enriched in LPC-DHA and LPC-EPA

    Aker BioMarine Human Ingredients AS · Expires Sep 25, 2045

    granted
  2. US 12331293

    Bispecific antisense oligonucleotides for dystrophin exon skipping

    BIOMARIN TECHNOLOGIES B.V. · Expires Jun 12, 2045

    granted
  3. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 27, 2045

    granted
  4. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 20, 2045

    granted
  5. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 30, 2045

    granted
  6. US 12194064

    Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids

    Aker BioMarine Human Ingredients AS · Expires Jan 9, 2045

    granted
  7. US 12188058

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 2, 2045

    granted
  8. US 12076372

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Expires Aug 29, 2044

    granted

Frequently asked questions

What is US patent 8349894?

US 8349894 (Compositions comprising an o/w emulsion containing conjugated linoleic acid) is held by Aker Biomarine AS. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8349894?

Aker Biomarine AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.

When does US 8349894 expire?

Our index shows an expiration date of Jan 3, 2033 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.